Edition:
United States

Profile: Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

152.20EUR
15 Jul 2019
Change (% chg)

-- (--)
Prev Close
€152.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
433,111
52-wk High
€154.60
52-wk Low
€74.48

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Company Address

Galapagos NV

Generaal De Wittelaan 3
MALINES (MECHELEN)     2800
P: +3215.342900
F: +3215.342901

Company Web Links